Target intelligence / Profile preview

Cyclin T2 (CCNT2)

Target
CCNT2
Molecular classification
Cyclin family protein, Transcription factor regulator, Regulatory subunit of cyclin-dependent kinase (CDK9/cyclin T complex), Regulatory subunit, Protein-binding domain
01

Overview

Cyclin T2 (CCNT2) is a regulatory protein encoded by the CCNT2 gene, part of the cyclin family characterized by cell cycle-dependent variation in abundance. It forms a core component of the CDK9/cyclin T complex (also known as positive transcription elongation factor b, P-TEFb), essential for phosphorylation of the RNA polymerase II C-terminal domain and thus for transcriptional elongation of many genes. Cyclin T2 plays roles in muscle differentiation, early viral transcription events (HIV, herpes simplex virus), and interacts with key cell cycle regulators like the Retinoblastoma protein. Multiple isoforms exist due to alternative splicing. Cyclin T2 is considered a target primarily in the context of viral transcription (HIV-1, herpesvirus) and is being explored for therapeutic disruption of these processes. Broader disease association is limited based on current sources.

Other names
Cyclin-T2CCNT2CycT2CYCT2cyclin-T2Cyclin T2aCyclin T2bCYCT2aCYCT2bsubunit of positive elongation transcription factor bP-TEFbSDS-stable vimentin-bound DNA fragment HEF42VIM22
02

Mechanism of action

Inhibition of P-TEFb (CDK9/cyclin T2 complex) disrupts phosphorylation of RNA polymerase II, blocking transcriptional elongation—this mechanism is closely studied in HIV research. Modulation of MYOD1-dependent transcription via interaction with PKN1, affecting muscle gene expression.

03

Biological functions

Regulation of cell cycleRegulation of transcription elongation (by RNA polymerase II)Positive regulation of phosphorylation of RNA polymerase II C-terminal domainRegulation of muscle cell differentiationInteracts with Retinoblastoma protein (cell cycle regulator)
04

Disease associations

Male infertilityHuman Immunodeficiency Virus Type 1 (HIV-1; acts as a negative regulator of HIV-1 Tat protein)Early and late herpes simplex virus 1 promoters (promotes transcriptional activation)No strong evidence for cancer, cardiovascular, or neurodegenerative roles in current results
05

Safety considerations

Targeting Cyclin T2 or its complex could interfere with general transcriptional regulation and cell cycle processes, potentially impacting normal cellular function.Therapeutic modulation may carry risks of toxicity due to broad involvement in gene expression.

Beyond the preview

Go deeper on Cyclin T2 (CCNT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin T2 (CCNT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call